Alnylam prepares to land first RNAi drug approval

Alnylam prepares to land first RNAi drug approval, Published online: 28 February 2018; doi:10.1038/nrd.2018.20

With Alnylam's rare disease drug candidate patisiran nearing the regulatory finish line, the RNA interference community is now turning its attention to next-generation delivery technology to solidify the future of the emerging modality.

中文翻译：

---

Alnylam准备获得首个RNAi药物批准

Alnylam准备获得首个RNAi药物批准

Alnylam准备获得首个RNAi药物批准，在线发布：2018年2月28日；doi：10.1038 / nrd.2018.20

随着Alnylam的罕见疾病候选药物patisiran接近监管终点线，RNA干扰界现在将注意力转向下一代递送技术，以巩固新兴疗法的未来。